Soleno Therapeutics, Inc. (SLNO)
NASDAQ: SLNO · Real-Time Price · USD
57.05
-0.06 (-0.11%)
Nov 8, 2024, 4:00 PM EST - Market closed
Company Description
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.
The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017.
Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
Soleno Therapeutics, Inc.
| Country | United States |
| Founded | 1999 |
| IPO Date | Nov 13, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 33 |
| CEO | Anish Bhatnagar |
Contact Details
Address: 203 Redwood Shores Parkway, Suite 500 Redwood City, California 94065 United States | |
| Phone | 650 213 8444 |
| Website | soleno.life |
Stock Details
| Ticker Symbol | SLNO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001484565 |
| CUSIP Number | 834203200 |
| ISIN Number | US8342033094 |
| Employer ID | 77-0523891 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Dr. Anish Bhatnagar M.D. | President, Chief Executive Officer, Chief Operating Officer and Director |
| James H. MacKaness | Chief Financial Officer |
| Patricia C. Hirano M.P.H. | Senior Vice President of Regulatory Affairs |
| Lauren Budesheim | Vice President of People |
| Kristen Yen M.S. | Senior Vice President of Clinical Operations |
| Dr. Neil M. Cowen M.B.A., Ph.D. | Senior Vice President of Drug Development |
| Meredith Manning M.B.A. | Chief Commercial Officer |
| Dr. Michael Huang M.D. | Senior Vice President of Clinical Development |
| Dr. Raymond W. Urbanski M.D., Ph.D. | Chief Development Officer |
| Dr. Mitchell Nagao M.B.A., Pharm.D. | Senior Vice President of Medical Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 6, 2024 | 8-K | Current Report |
| Nov 6, 2024 | 10-Q | Quarterly Report |
| Oct 24, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 21, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Oct 21, 2024 | 144 | Filing |
| Oct 15, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Oct 10, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Oct 7, 2024 | 144 | Filing |
| Oct 3, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Sep 10, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |